Identification of cytochrome P450 enzymes involved in the metabolism of zotepine, an antipsychotic drug, in human liver microsomes

References

• AKAIKE, H., 1974, A new look at the statistical model identification. IEEE Transactions on Automatic Control, 19, 716–723.
   Web of Science ®Google Scholar
• ANDERSSON T., MINERS, J. 0., VERONESE M. E. and BIRKETT, D. J., 1994, Diazepam metabolism by human liver microsomes is mediated by both S-mephenytoin hydroxylase and CYP3A isoforms. British Journal of Clinical Pharmacology, 38, 131–137.
   Google Scholar
• BACK, D. J., THA, J. F., KARBWANG, J. and COLBERT, J., 1988, In vitro inhibition studies of tolbutamide hydroxylase activity of human liver microsomes by azoles, sulphonamides and quinolines. British Journal of Clinical Pharmacology, 26, 23–29.
   PubMed Web of Science ®Google Scholar
• BALDWIN, S. J., BLOOMER, J. C., SMITH, G. J., AYRTON, A. D., CLARICE, S. E. and CHENERY, R. J., 1995, Ketoconazole and sulphaphenazole as the respective selective inhibitors of P4503A and 2C9. Xenobiotica, 25, 261–270.
   PubMed Web of Science ®Google Scholar
• BARNAS, C., STUPPÄCK, C. H., MILLER, C., HARING, C., SPERNER -UNTERWEGER, B. and FLEISCHHACKER W. W., 1992, Zotepine in the treatment of schizophrenic patients with prevailingly negative symptoms. A double-blind trial vs. haloperidol. International Clinical Psychopharmacology, 7, 23–27.
   Google Scholar
• BERTZ, R. J. and GRANNEMAN, R., 1997, Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clinical Pharmacokinetics, 32, 210–258.
   PubMed Web of Science ®Google Scholar
• FLEISCHHACKER W. W., BARNAS, C., STUPPÄCK, C. H., UNTERWEGER, B., MILLER, C. and HINTERHUBER H., 1989, Zotepine vs. haloperidol in paranoid schizophrenia: a double-blind trial. Psycho-pharmacology Bulletin, 25, 97–100.
   PubMed Web of Science ®Google Scholar
• GOLDSTEIN, J. A., FALETTO, M. B., ROMKES -SPARKS, M., SULLIVAN, T., KITAREEWAN, S., RAUCY, J. L., LASKER, J. M. and GHANAYEN, B. I., 1994, Evidence that CYP2C19 is the major (S)-mephenytoin 4'-hydroxylase in humans. Biochemistry, 33, 1743–1752.
   Google Scholar
• GUENGERICH F. P., KIM, D.-H. and IWASAKI, M., 1991, Role of human cytochrome P-450 IIE1 in the oxidation of many low molecular weight cancer suspects. Chemical Research in Toxicology, 4, 168–179.
   PubMed Web of Science ®Google Scholar
• HEBERT, M. F., ROBERTS, J. P., PRUEKSARITANONT, T. and BENET, L. Z., 1992, Bioavailability of cyclosporine with concomitant rifampin administration is markedly less than predicted by hepatic enzyme induction. Clinical Pharmacology and Therapeutics, 52, 453–457.
   PubMed Web of Science ®Google Scholar
• HIGASHI, Y., MOMOTANI, Y., Suzum, E. and KAKU, T., 1987, Clinical and EEG studies of zotepine, a thiepine neuroleptic, on schizophrenic patients. Pharmacopsychiatrie, 20, 8–11.
   PubMed Web of Science ®Google Scholar
• INOUE, K., YAMAZAKI, H., ImIYA, K., AKASAKA, S., GUENGERICH, F. P. and SHIMADA, T., 1997, Relationship between CYP2C9 and 2C19 genotypes and tolbutamide methyl hydroxylation and S-mephenytoin 4"-hydroxylation activities in livers of Japanese and Caucasian populations. Pharmacogenetks, 7, 103–113.
   Google Scholar
• KOLARS, J. C., LOWN, K. S., SCHMIEDLIN -REN, P., GHOSH, M., FANG, C., WRIGHTON, S. A., MERION, R. M. and WATKINS, P. B., 1994, CY P3A gene expression in human gut epithelium. Pharmaco-genetics, 4, 247–259.
   Google Scholar
• LAWTON, M. P., CASHMAN, J. R., CRESTEIL, T., DOLPHIN, C. T., ELFARRA, A. A., HINES, R. N, HODGSON, E., KIMURA, T., OZOLS, J., PHILLIPS, I. R., PHILPOT, R. M., POULSEN, L. L., RETTIE A. E., SHEPHARD, E. A., WILLIAMS, D. E. and ZIEGLER, D. M., 1994, A nomenclature for the mammalian flavin-containing monooxygenase gene family based on amino acid sequence identities. Archives of Biochemistry and Biophysics, 308, 254–257.
   Google Scholar
• NELSON D. R., KOYMANS, L., KAMATAKI, T., STEGEMAN J. J., FEYEREISEN, R. WAXMAN, D. J., WATERmAN, M. R., GOTOH, 0., COON, M. J., ESTABROOK, R. W., GUNSALUS I. C. and NERBERT D. W., 1996, P450 superfamily : update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics, 6, 1–42.
   Google Scholar
• NEWTON, D. J., WANG, R. W. and Lu, A. Y. H., 1995, Cytochrome P450 inhibitors: evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metabolism and Disposition, 23, 154–158.
   PubMed Web of Science ®Google Scholar
• NODA, K., Suzum, A., Oxm, M., NOGUCHI, H., NISHIURA, M. and NISHIURA, N., 1979, Pharmacokinetics and metabolism of 2-chloro-11-(2-dimethylaminoethoxy)-dibenzo[bj]thiepine (zotepine) in rat, mouse, dog and man. Arzneimittel-Forschung/Drug Research, 29, 1595–1600.
   PubMed Web of Science ®Google Scholar
• ONO, S., HATANAKA, T., MIYAZAWA, S., TSUTSUI, M., AOYAMA, T., GONZALEZ, F. J. and SATOH, T., 1996, Human liver microsomal diazepam metabolism using cDNA-expressed cytochrome P450s : role of CYP2B6,2C19 and the 3A subfamily. Xenobiotica, 26, 1155–1166.
   PubMed Web of Science ®Google Scholar
• OTANI, K., KONDO, T., KANEKO, S., HIRANO, T., MIHARA, K. and FUKUSHEVIA Y, 1992, Steady-state serum kinetics of zotepine. Human Psychopharmacology, 7, 331–336.
   Google Scholar
• OTTON, S. V., CREWE, H. K., LENNARD, M. S., TUCKER, G. T. and WOODS, H. F., 1988, Use of quinidine inhibition to define the role of the sparteine/debrisoquine cytochrome P450 in metoprolol oxidation by human liver microsomes. Journal of Pharmacology and Experimental Therapeutics, 247, 242–247.
   PubMed Web of Science ®Google Scholar
• PASTRAKULJIC, A., TANG, B. K., ROBERTS, E. A. and KALO W., 1997, Distinction of CYP1A1 and CYP1A2 activity by selective inhibition using fluvoxamine and isosafrole. Biochemical Phar-macology, 53, 531–538.
   PubMed Web of Science ®Google Scholar
• SESARDIC, D., BOOBIS, A. R., MURRAY, B. P., SEGURA, M. J., DE LA TORRE, R. and DAVIES, D. S., 1990, Furafylline is a potent and selective inhibitor of cytochrome P4501A2 in man. British Journal of Clinical Pharmacology, 29, 651–663.
   PubMed Web of Science ®Google Scholar
• SHIMADA, T., YAMAZAKI, H., MIMURA, M., INUI, Y. and GUENGERICH, F. P., 1994, Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. Journal of Pharmacology and Experimental Therapeutics, 270, 414–423.
   PubMed Web of Science ®Google Scholar
• TANAKA, 0., 1996, Pharmacokinetics of zotepine and various factors affecting that of zotepine. Japanese Journal of Psychopharmacology, 16, 49–52.
   Google Scholar
• THUMMEL, K. E., O'SHEA, D PM NE, M. F., SHEN, D. D., KUNZE, K. L., PERKINS, J. D. and WILKINSON, G. R., 1996, Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism. Clinical Pharmacology and Therapeutics, 59, 491–502.
   Google Scholar
• UCHIDA, S., HONDA, F., OTSUKA, M., SATOH, Y., MORI, J., ONO, T. and HITOMI, M., 1979, Pharmaco-logical study of [2-chloro-11-(2-dimethylaminoethoxy)dibenzo[kf]thiepine] (zotepine), a new neuroleptic drug. Arzneimittel-Forschung/Drug Research, 29, 1588–1594.
   PubMed Web of Science ®Google Scholar
• WRIGHTON, S. A., BRIAN, W. R., SARI, M.-A., IWASAKI, M., GUENGERICH, F. P., RAUCY, J. L., MOLOWA D. T. and VANDENBRANDEN, M., 1990, Studies on the expression and metabolic capabilities of human liver cytochrome P450IIIA5 (HLp3). Molecular Pharmacology, 38, 207–213.
   Google Scholar
• YAMAOKA, K., TANIGAWARA, Y., NAKAGAwA, T. and UNO, T., 1981, A pharmacokinetic analysis program (MULTI) for microcomputer. Journal of Pharmacobio-Dynamics, 4, 879–885.
   PubMedGoogle Scholar
• ZIEGLER, D. M., 1988, Flavin-containing monooxygenases : catalytic mechanism and substrate specifi-cities. Drug Metabolism Reviews, 19, 1–32.
   PubMed Web of Science ®Google Scholar